PLoS ONE (Jan 2014)

Plasmodium vivax antigen discovery based on alpha-helical coiled coil protein motif.

  • Nora Céspedes,
  • Catherine Habel,
  • Mary Lopez-Perez,
  • Angélica Castellanos,
  • Andrey V Kajava,
  • Catherine Servis,
  • Ingrid Felger,
  • Remy Moret,
  • Myriam Arévalo-Herrera,
  • Giampietro Corradin,
  • Sócrates Herrera

DOI
https://doi.org/10.1371/journal.pone.0100440
Journal volume & issue
Vol. 9, no. 6
p. e100440

Abstract

Read online

Protein α-helical coiled coil structures that elicit antibody responses, which block critical functions of medically important microorganisms, represent a means for vaccine development. By using bioinformatics algorithms, a total of 50 antigens with α-helical coiled coil motifs orthologous to Plasmodium falciparum were identified in the P. vivax genome. The peptides identified in silico were chemically synthesized; circular dichroism studies indicated partial or high α-helical content. Antigenicity was evaluated using human sera samples from malaria-endemic areas of Colombia and Papua New Guinea. Eight of these fragments were selected and used to assess immunogenicity in BALB/c mice. ELISA assays indicated strong reactivity of serum samples from individuals residing in malaria-endemic regions and sera of immunized mice, with the α-helical coiled coil structures. In addition, ex vivo production of IFN-γ by murine mononuclear cells confirmed the immunogenicity of these structures and the presence of T-cell epitopes in the peptide sequences. Moreover, sera of mice immunized with four of the eight antigens recognized native proteins on blood-stage P. vivax parasites, and antigenic cross-reactivity with three of the peptides was observed when reacted with both the P. falciparum orthologous fragments and whole parasites. Results here point to the α-helical coiled coil peptides as possible P. vivax malaria vaccine candidates as were observed for P. falciparum. Fragments selected here warrant further study in humans and non-human primate models to assess their protective efficacy as single components or assembled as hybrid linear epitopes.